Filing Flows › Comparisons › KURA vs RAPP
Kura Oncology vs Rapport Therapeutics: KURA and RAPP compared
Kura Oncology is the larger company: $20.9M of revenue in its latest quarter (Q2 2026) against $20.0M for Rapport Therapeutics (Q1 2026). Rapport Therapeutics is more profitable, with an operating margin of -121.1% against -349.8%.
Where the money goes: KURA and RAPP
Kura Oncology (KURA) · Q2 2026
Kura Oncology, Q2 2026: revenue $20.9M (+36% year over year), operating margin -349.8%, net loss $68.3M, operating cash flow −$62.5M. The chart follows the revenue to costs, profit and cash.
Rapport Therapeutics (RAPP) · Q1 2026
Rapport Therapeutics, Q1 2026: revenue $20.0M, operating margin -121.1%, net loss $19.9M, operating cash flow −$13.1M. The chart follows the revenue to costs, profit and cash.
| Kura Oncology (KURA) | Rapport Therapeutics (RAPP) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 2026 |
| Revenue | $20.9M | $20.0M |
| Revenue growth, Y/Y | +36% | — |
| Operating margin | -349.8% | -121.1% |
| Net earnings | −$68.3M | −$19.9M |
| Net margin | -327.3% | -99.3% |
| Operating cash flow | −$62.5M | −$13.1M |
Where the revenue comes from
Kura Oncology
- License and Collaboration Revenue: $11.8M (56%)
- Product: $9.1M (44%)
Questions
Which is bigger, Kura Oncology or Rapport Therapeutics?
Kura Oncology is the larger company: $20.9M of revenue in its latest quarter (Q2 2026) against $20.0M for Rapport Therapeutics (Q1 2026).
Is Kura Oncology or Rapport Therapeutics growing faster?
Rapport Therapeutics is more profitable, with an operating margin of -121.1% against -349.8%.
More: Kura Oncology earnings · how Kura Oncology makes money · Rapport Therapeutics earnings · how Rapport Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed May 7, 2026). Fiscal quarters can end on different dates. Not investment advice.